List of figures, tables and boxes

Chapter I

Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.1</td>
<td>Leading causes of disease burden in DALYs in 2000 and 2016 globally</td>
<td>34</td>
</tr>
<tr>
<td>Figure 1.2</td>
<td>Leading causes of death in 2000 and 2016 globally</td>
<td>34</td>
</tr>
<tr>
<td>Figure 1.3</td>
<td>Global burden of disease ranking, 1990 and 2017</td>
<td>35</td>
</tr>
<tr>
<td>Figure 1.4</td>
<td>The distinct policy domains of public health</td>
<td>37</td>
</tr>
<tr>
<td>Figure 1.5</td>
<td>Policy intersections between distinct levels</td>
<td>38</td>
</tr>
</tbody>
</table>

Boxes

<table>
<thead>
<tr>
<th>Box</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Box 1.1</td>
<td>WHO–WIPO–WTO technical symposia</td>
<td>32</td>
</tr>
<tr>
<td>Box 1.2</td>
<td>The disability-adjusted life year (DALY)</td>
<td>33</td>
</tr>
<tr>
<td>Box 1.3</td>
<td>Health and medical technologies: fundamental concepts</td>
<td>39</td>
</tr>
</tbody>
</table>

Chapter II

Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 2.1</td>
<td>Key challenges in implementing national action plans</td>
<td>52</td>
</tr>
<tr>
<td>Figure 2.2</td>
<td>Stewardship, innovation and access: a delicate balance of conflicting goals</td>
<td>52</td>
</tr>
<tr>
<td>Figure 2.3</td>
<td>Illustration of terms of patent protection and regulatory exclusivities</td>
<td>61</td>
</tr>
<tr>
<td>Figure 2.4</td>
<td>Growth of the top four technology fields, 2000–2019</td>
<td>79</td>
</tr>
<tr>
<td>Figure 2.5</td>
<td>PCT applications in the field of medical technology, including pharmaceuticals, 2000–2019</td>
<td>79</td>
</tr>
<tr>
<td>Figure 2.6</td>
<td>Main countries of origin of PCT publications in the field of medical technology, including pharmaceuticals, 2000–2019</td>
<td>80</td>
</tr>
</tbody>
</table>

Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 2.1</td>
<td>Information available in MedsPaL and Pat-INFORMED</td>
<td>75</td>
</tr>
<tr>
<td>Table 2.2</td>
<td>Examples of search parameters for pharmaceutical substances</td>
<td>77</td>
</tr>
<tr>
<td>Table 2.3</td>
<td>Number of GATS commitments</td>
<td>101</td>
</tr>
<tr>
<td>Table 2.4</td>
<td>Coverage in the health sector by parties to the WTO GPA</td>
<td>104</td>
</tr>
</tbody>
</table>

Boxes

<table>
<thead>
<tr>
<th>Box</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Box 2.1</td>
<td>Selected reports on access to medicines and R&amp;D</td>
<td>47</td>
</tr>
<tr>
<td>Box 2.2</td>
<td>The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property</td>
<td>50</td>
</tr>
<tr>
<td>Box 2.3</td>
<td>CRISPR-Cas9 gene-editing technology</td>
<td>58</td>
</tr>
<tr>
<td>Box 2.4</td>
<td>CAR T-cell therapy</td>
<td>58</td>
</tr>
<tr>
<td>Box 2.5</td>
<td>Selected types of US regulatory exclusivity</td>
<td>60</td>
</tr>
<tr>
<td>Box 2.6</td>
<td>The Paris Convention</td>
<td>64</td>
</tr>
<tr>
<td>Box 2.7</td>
<td>TRIPS and public health: key milestones</td>
<td>65</td>
</tr>
<tr>
<td>Box 2.8</td>
<td>The Patent Cooperation Treaty</td>
<td>67</td>
</tr>
<tr>
<td>Box 2.9</td>
<td>Societal and moral values in the patent system</td>
<td>69</td>
</tr>
</tbody>
</table>
Box 2.10  WIPO Standing Committee on the Law of Patents 73
Box 2.11  Selected databases 75
Box 2.12  The example of colchicine 83
Box 2.13  The Madrid System for the International Registration of Marks 84
Box 2.14  Artificial intelligence and health 89
Box 2.15  Definition of flexibilities according to WIPO 92
Box 2.16  TRIPS flexibilities highlighted in the GSPA-PHI and Road Map for Access to Medicines, Vaccines and Other Health Products, 2019–2023 92
Box 2.17  The example of Cambodia: an LDC’s terms of accession to the WTO 95
Box 2.18  Merger control in the European Union 97
Box 2.19  Antimicrobial resistance in the SPS Committee 100
Box 2.20  Product patents and access to innovative medicines in a post-TRIPS era 110
Box 2.21  The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity (Nagoya Protocol) 115

Chapter III

Figures

Figure 3.1  Approvals of medicines by the US Food & Drug Administration, 1944–2019 135
Figure 3.2  Global R&D expenditures, PCT international application publications on pharmaceuticals and novel drug approvals in the United States, 2004–2019 135
Figure 3.3  Novel drug approvals, percentage with orphan designation and R&D expenditure as percentage of sales, 1999–2019 136
Figure 3.4  Patent publications by technology: performance by sector, income group and world, 1980–2017 137
Figure 3.5  Top countries of origin of PCT publications in the field of pharmaceuticals, 1996–2019 139
Figure 3.6  The innovation cycle 144
Figure 3.7  Timeline of the discovery of different antibiotic classes in clinical use 153
Figure 3.8  Number and sales values of PRVs 160

Tables

Table 3.1  PRVs issued, 2009–2019 159
Table 3.2  Pharmaceutical industry centres dedicated to NTDs R&D 164
Table 3.3  IP issues that may arise at each stage of the product development pipeline 167
Table 3.4  The different roles of patents in the medical devices industry and the pharmaceutical industry 169
Table 3.5  Summary of benefit-sharing options under SMTA 2 182

Boxes

Box 3.1  IP and licensing in the discovery of insulin 134
Box 3.2  Adaptation of medical devices to developing-country needs – the example of portable electrocardiographs 141
Box 3.3  Monoclonal antibodies 142
Box 3.4  New innovation models in practice: tailoring a meningitis vaccine for Africa 146
Chapter IV

Figures

Figure 4.1 The WHO Health System Framework 193
Figure 4.2 The three dimensions of universal health coverage 194
Figure 4.3 Ensuring access along the value chain of medicines and health products 195
Figure 4.4 Local production and access to essential medical products: a framework for improving public health 211
Figure 4.5 Sales revenue per year of generic and originator ARVs in LMICs 218
Figure 4.6 Sales quantities per year of generic and originator ARVs in LMICs 219
Figure 4.7 Challenges in access to AMR-related technologies in LMICs 220
Figure 4.8 Detention of generic medicines in transit by EU Customs 251
Figure 4.9 Evolution of IP chapters in FTAs: developments from 2000 to 2019 257
Figure 4.10 Imports of health-related products 1995–2018, by value (in US$ million) and compound growth rates, 2018 264
Figure 4.11 Per capita imports of pharmaceutical formulations 1995–2018 267
Figure 4.12 Tariffs on health-related products: simple applied average versus WTO simple bound average rates, by product category, 2018 268

Tables

Table 4.1 Selected country experiences with compulsory licences and government-use licences 239
Table 4.2 Comparison of expected patent expiry dates and dates of SPC expiry in France, for selected medicines on the WHO EML 249
Table 4.3 Provisions in selected FTAs with a bearing on access and innovation in the pharmaceutical sector 253
Table 4.4 Public-health-related products 263
Table 4.5 International trade in health-related products: share of main importers, 2018 264
Table 4.6 International trade in health-related products: share of main exporters, 2018 265
Table 4.7 Net exporters of pharmaceutical products (categories A1, A2, A3), average 2016–2018 266
Table 4.8 Net importers of pharmaceutical products (categories A1, A2, A3), average 2016–2018 266
Table 4.9 Share of health product imports in total national imports, 2018 267

Boxes

Box 4.1 The US Hatch-Waxman Act as a supply-side measure to encourage generic competition 197
Box 4.2 Price control and reference prices to reduce prices of medicines in Colombia 199
Box 4.3 Examples of databases of medicines prices 202
Box 4.4 Differential packaging 203
Box 4.5 Authorized generics 203
Box 4.6 The WHO Model List of Essential Medicines 205
Box 4.7 Cost reduction/improvements in value for money in the health-care sector through centralized procurement: the example of Ecuador 207
Box 4.8 Examples of European pooled procurement initiatives: the Beneluxa Initiative and the Joint Procurement Mechanisms 208
Box 4.9 Developing local production capacities in Ghana: support measures and challenges 210
Box 4.10 Europe: tightening controls to guarantee the safety of medical devices 212
Box 4.11 WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products 216
Box 4.12 Innovative Medicines for Tuberculosis (iM4TB) Foundation 221
Box 4.13 WHO, Pricing of Cancer Medicines and its Impacts (2019) 222
Box 4.14 Access to insulin 223
Box 4.15 Buyers’ clubs 225
Box 4.16 Gavi, the Vaccine Alliance 226
Box 4.17 Precision medicine and the patentability of diagnostic and treatment methods 231
Box 4.18 Guidelines for the examination of pharmaceutical patents: developing a public health perspective 232
Box 4.19 The US Patent Trial and Appeal Board 234
Box 4.20 Government-use licences: efavirenz and lopinavir/ritonavir in Thailand 236
Box 4.21 Government-use licences: hepatitis C treatment in Malaysia 237
Box 4.22 Compulsory licences as a litigation tool 239
Box 4.23 Case study on supply of ARVs to Rwanda 243
Box 4.24 The Medicines Patent Pool 245
Box 4.25 Access to Medicine Index 246
Box 4.26 Cases under IIAs and FTAs 260
Box 4.27 The emergence of global value chains 265
Box 4.28 How tariff reductions can save human lives: the example of mosquito nets 268
Box 4.29 Sectoral tariff negotiations in the GATT and the WTO 269
Box 4.30 The WTO Trade Facilitation Agreement 270
Box 4.31 Competition investigation into strategic patenting – cases from South Africa 271
Box 4.32 Action against sham litigation in the pharmaceutical sector in Brazil 272
Box 4.33 Landmark reverse patent settlement ruling by the Supreme Court of the United States and subsequent developments 272
Box 4.34  The European Union’s Guidelines on Technology Transfer Agreements, monitoring and enforcement against reverse patent settlements in the pharmaceutical sector 273
Box 4.35  Competition law enforcement against a reverse patent settlement in the Republic of Korea 273
Box 4.36  Abuse of dominance in South Africa 273
Box 4.37  Applying competition law to generic manufacturers 275
Box 4.38  General approaches to “excessive pricing” in domestic laws 275
Box 4.39  Examples of “excessive pricing” cases concerning pharmaceuticals 275
Box 4.40  Jurisprudence on competition authority scrutiny to enable competition through off-label use 276
Box 4.41  Hospital merger in Brazil 276
Box 4.42  The 2019 Health Market Inquiry of the Competition Commission of South Africa 277

Annexes
Tables

Resolutions of the UN General Assembly and UN Human Rights Council
Key Reports of the UN Special Rapporteur on the Right to Health 292
Selected Resolutions and Decisions of the World Health Assembly 298
Special Compulsory Licences for Export of Medicines 302